• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke
AbstractPost-stroke lower limb spasticity impairs balance and gait leading to reduced walking speed, often increasing wheelchair use and caregiver burden. Several studies have shown that appropriate treatments for lower limb spasticity after stroke include injections of botulinum toxin type A (BoNT-A), phenol or alcohol, surgical correction and a rehabilitation program. In the present article, we review the safety and effectiveness of BoNT-A for the treatment of lower limb spasticity after stroke, with a focus on higher doses of BoNT-A. The cumulative body of evidence coming from the randomized clinical trials and open-lab...
Source: Drugs - January 8, 2019 Category: Drugs & Pharmacology Source Type: research

Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment
AbstractBotulinum toxin type A (BoNT-A) is considered the gold standard for the treatment of focal post-stroke spasticity (PSS). However, a recently published study estimated that a significant percentage of patients affected by PSS could benefit from higher doses of BoNT-A than those permitted by current directives in the countries studied. Several studies have reported the use of high doses of BoNT-A in the management of patients affected by severe PSS; however, the most important adverse effect of this drug might be systemic diffusion of the toxin, which could potentially be related to its dose. Even if systemic toxicit...
Source: Clinical Drug Investigation - September 12, 2018 Category: Drugs & Pharmacology Source Type: research

Pain and muscles properties modifications after botulinum toxin type A (BTX-A) and radial Extracorporeal Shock Wave (rESWT) combined treatment.
CONCLUSIONS: Radial Extracorporeal Shock Wave Therapy could be an effective physical treatment aimed at the reduction of upper and lower limbs spasticity and could lead to the improvement of trophic conditions of the spastic muscles in post-stroke. PMID: 30843498 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - March 8, 2019 Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research

Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity
AbstractSpasticity with muscle paresis and loss of dexterity is a common feature of upper motor neuron syndrome due to injuries or the pyramidal tract in several neurological conditions. Botulinum toxin type A has been considered the gold standard treatment for spasticity and movement disorders, with efficacy, reversibility, and low prevalence of complications. During the last 30  years, thousands of studies of its use have been performed, but few guidelines are available. Therefore, there is great variability in both the doses and intervals of administration and the approaches taken by clinicians with considerable experi...
Source: Drugs - July 19, 2017 Category: Drugs & Pharmacology Source Type: research

Clinical Onset of Action of Incobotulinum Toxin A Preparation
CONCLUSION: This study demonstratedthe onset of IncobotulinumtoxinA efficacy started after 7 days; this rapid action and efficacy of BoNT/A preparation could improve an intensive rehabilitation program after some days post injection. Early clinical onset of action could be by the absence of complexing proteins in the preparation.PMID:35786195 | DOI:10.2174/1871527321666220630154404
Source: CNS and Neurological Disorders Drug Targets - July 5, 2022 Category: Drugs & Pharmacology Authors: Riccardo Marvulli Maurizio Ranieri Laura Belinda Rizzo Francesco Marra Giancar Lo Ianieri Marisa Megna Source Type: research